Innovative Targeted Oncology Therapies

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2005-10-04

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The targeted therapies market is relatively new in comparison to the cytotoxic and anti-hormonal therapies markets, and will therefore continue to show double-figure growth across the seven major pharmaceutical markets to 2014. Despite products which have already established gold-standard status within specific tumor types, ample lucrative opportunities exist for pipeline candidates in the market.


Scope

  • Overview of the current targeted therapies market, including profiles of key products and events impacting each during 200414
  • Examination of the targeted therapies pipeline with in-depth clinical and commercial profiles of Phase III candidates, plus expert opinion
  • Seven-market sales forecasts from 2004 to 2014 for branded targeted therapies and key pipeline candidates
  • Detailed discussion of key strategic issues in the targeted therapies market, plus three commercial impact and lifecycle management case studies


    • Report Highlights
    The market for existing targeted therapies was worth $5.1 billion in 2004, and is set to grow at a CAGR of 13.7% to reach $13.7 billion by 2014. This is due to the novelty of this market, allowing for further increasing sales of current marketed products, with no immediate threat from patent expiries and generic competition.

    This sustained growth will allow established products such as Genentech/Roche's Rituxan and Novartis' Glivec to maintain their blockbuster status, while allowing newer products such as Genentech/Roche's Herceptin, Avastin and Tarceva to break the $1 billion sales barrier within the forecast period.

    The introduction of high-potential pipeline products will increase the total market value of targeted therapies to $19.2 billion by 2014. Those products developed to inhibit multiple pathways show the most promise, particularly Onyx Pharmaceuticals/Bayer's sorafenib and Bristol-Myers Squibb's dasatinib, with forecast sales of over $800m by 2014.


    Reasons to Purchase

  • Understand market specific drivers and predict the future potential of key marketed and pipeline targeted therapies
  • Assess the impact of product launches and identify the opportunities and risks for key products within the targeted therapies market
  • Adopt knowledge to drive strategic planning for marketed products and optimize the market penetration of new entrants

    • Table of Contents

    Other users found this report page using the following search terms: targeted therapy kinase immunotherapy transmid terminated powerpoint presentations egfr glioma vatalinib schering healthcare generic

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.